Start of Dicot's phase 1 trial booked for August
Press release: Uppsala, May 2, 2023. Dicot's development of its potency drug candidate LIB-01 is proceeding according to plan and the company has now scheduled the start of its phase 1 trial for August 2023 at CTC AB who will conduct the study.Dicot is developing a new potency drug that aims to become the first choice of treatment for erectile dysfunction and premature ejaculation. The company has previously announced that it intends to start clinical phase 1 trial on the drug candidate LIB-01 in mid-2023. To ensure a start according to plan, the company has now reserved capacity at the